Zeke Capital Advisors LLC Increases Stock Holdings in Colgate-Palmolive (NYSE:CL)

Zeke Capital Advisors LLC increased its holdings in shares of Colgate-Palmolive (NYSE:CL) by 1.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,057 shares of the company’s stock after buying an additional 795 shares during the period. Zeke Capital Advisors LLC’s holdings in Colgate-Palmolive were worth $4,448,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Meridian Wealth Management LLC purchased a new position in Colgate-Palmolive in the 1st quarter valued at $29,000. Lipe & Dalton purchased a new position in Colgate-Palmolive in the 2nd quarter valued at $29,000. WP Advisors LLC purchased a new position in Colgate-Palmolive in the 1st quarter valued at $34,000. Princeton Global Asset Management LLC purchased a new position in Colgate-Palmolive in the 1st quarter valued at $43,000. Finally, Paragon Capital Management LLC purchased a new position in Colgate-Palmolive in the 1st quarter valued at $46,000. Hedge funds and other institutional investors own 75.52% of the company’s stock.

Shares of CL traded down $0.06 during midday trading on Friday, reaching $71.20. The company had a trading volume of 3,813,538 shares, compared to its average volume of 3,524,740. The business has a 50 day simple moving average of $73.13. The company has a debt-to-equity ratio of 32.25, a quick ratio of 0.78 and a current ratio of 1.13. The company has a market capitalization of $61.14 billion, a PE ratio of 23.97, a PEG ratio of 4.59 and a beta of 0.76. Colgate-Palmolive has a 1-year low of $57.41 and a 1-year high of $76.41.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings data on Friday, July 26th. The company reported $0.72 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.72. The firm had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.88 billion. Colgate-Palmolive had a negative return on equity of 10,821.98% and a net margin of 14.77%. The company’s quarterly revenue was down .5% on a year-over-year basis. During the same period last year, the company earned $0.77 EPS. On average, sell-side analysts predict that Colgate-Palmolive will post 2.84 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Thursday, July 18th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 2.42%. The ex-dividend date of this dividend is Wednesday, July 17th. Colgate-Palmolive’s payout ratio is 57.91%.

CL has been the topic of a number of research reports. Deutsche Bank raised their price objective on Colgate-Palmolive from $74.00 to $76.00 and gave the company a “hold” rating in a report on Friday, July 12th. Jefferies Financial Group raised their target price on Colgate-Palmolive from $61.00 to $73.00 and gave the stock an “in-line” rating in a research note on Monday, April 29th. They noted that the move was a valuation call. Wells Fargo & Co raised their target price on Colgate-Palmolive from $68.00 to $70.00 and gave the stock a “market perform” rating in a research note on Monday, July 29th. UBS Group raised their target price on Colgate-Palmolive from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Finally, Macquarie raised their target price on Colgate-Palmolive from $65.00 to $72.00 and gave the stock a “neutral” rating in a research note on Monday, April 29th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $73.13.

In related news, VP Philip G. Shotts sold 8,800 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $71.66, for a total transaction of $630,608.00. Following the completion of the sale, the vice president now directly owns 50,032 shares of the company’s stock, valued at approximately $3,585,293.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP John J. Huston sold 473 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $72.93, for a total value of $34,495.89. Following the sale, the senior vice president now directly owns 59,668 shares of the company’s stock, valued at $4,351,587.24. The disclosure for this sale can be found here. Insiders have sold a total of 422,925 shares of company stock valued at $30,478,467 over the last three months. Corporate insiders own 1.14% of the company’s stock.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.

Further Reading: What is a front-end load?

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.